Please wait a minute...
浙江大学学报(医学版)  2015, Vol. 44 Issue (5): 473-478    DOI: 10.3785/j.issn.1008-9292.2015.09.01
述评     
分子靶向抗肿瘤药物的毒性研究进展
娄小娥, 陈敏, 杨波
浙江大学药学院药理毒理与生化药学研究所, 浙江杭州 310058
Research progress in toxicology of molecular targeted anticancer drugs
LOU Xiao-e, CHEN Min, YANG Bo
Institute of Pharmacology & Toxicology and Biochemical Pharmaceutics, Zhejiang University, Hangzhou 310058, China
全文: PDF(696 KB)  
摘要: 

目的:药物治疗是肿瘤治疗的重要手段,传统的化疗药物疗效欠佳、副作用大,因此以酪氨酸激酶抑制剂为代表的分子靶向抗肿瘤药物得到大力发展。分子靶向抗肿瘤药物具有靶向性强、疗效显著等特点,但在临床应用的过程中会对心、肝、肺等重要脏器造成不同程度的损伤以及引发手足综合征等不良反应,极大地限制其在临床的应用和发展。因此,分析分子靶向抗肿瘤药物的毒性反应临床现状,研究其作用机制及保护干预措施已成为药物毒理学研究的重要任务。

关键词 抗肿瘤药/毒性蛋白酪氨酸激酶类/拮抗剂和抑制剂蛋白酪氨酸激酶类/副作用心脏/药物作用肝/药物作用肺/药物作用皮肤疾病综述    
Abstract

Objective:Drug therapy is essential for cancer treatment. The molecular targeted anticancer drugs develop rapidly in recent years, since the effectiveness of traditional chemotherapy is unsatisfactory and the adverse reactions are high. However, molecular targeted anticancer drugs would damage the function of heart, liver or lung, and may cause adverse effects such as hand-foot syndrome, which restrains their clinical application. Therefore, it is critical for pharmaceutical toxicology to study the toxicity, the related mechanisms and the preventive measures of molecular targeted anticancer drugs.

Key wordsAntineoplastic agents/toxicity    Protein-tyrosine kinases/antagonists &    inhibitors    Protein-tyrosine kinases/adverse effects    Heart/drug effects    Liver/drug effects    Lung/drug effects    Skin diseases/etiology    Review
收稿日期: 2015-05-28
CLC:  R96  
基金资助:

国家重大新药创制专项(2009ZX09303-004)

通讯作者: 杨波(1971-),女,博士,教授,博士生导师,从事抗肿瘤药物的药理学研究;E-mail:yang924@zju.edu.cn;http://orcid.org/0000-0002-6505-2771     E-mail: yang924@zju.edu.cn
作者简介: 娄小娥(1971-),女,博士研究生,从事抗肿瘤药物临床药理研究;E-mail:louxiaoe@zju.edu.cn;http://orcid.org/0000-0003-1587-5419
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  

引用本文:

娄小娥等. 分子靶向抗肿瘤药物的毒性研究进展[J]. 浙江大学学报(医学版), 2015, 44(5): 473-478.
LOU Xiao-e, CHEN Min, YANG Bo. Research progress in toxicology of molecular targeted anticancer drugs. Journal of ZheJiang University(Medical Science), 2015, 44(5): 473-478.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2015.09.01      或      http://www.zjujournals.com/xueshu/med/CN/Y2015/V44/I5/473

[1] DASSONVILLE O, BOZEC A, FISCHEL J L, et al. EGFR targeting therapies:monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences[J]. Crit Rev Oncol Hemat, 2007,62(1):53-61.
[2] ZHANG S, LIU X, BAWA-KHALFE T,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012,18(11):1639-1942.
[3] RASCHI E, VASINA V, URSINO M G, et al. Anticancer drugs and cardiotoxicity:insights and perspectives in the era of targeted therapy[J]. J Pharmacol Exp Ther, 2010,125(2):196-218.
[4] OLSON E M, ABDEL-RASOUL M, MALY J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab[J]. Ann Oncol, 2013,24(6):1526-1533.
[5] ATALLAH E, DURAND J B, KANTARJIAN H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy[J]. Blood, 2007,110(4):1233-1237.
[6] FRANCIS J, AHLUWALIA M S, WETZLER M, et al. Reversible cardiotoxicity with tyrosine kinase inhibitors[J]. Clin Adv Hematol Oncol, 2010,8(2):128-132.
[7] ORPHANOS G S, IOANNIDIS G N, ARDAVANIS A G. Cardiotoxicity induced by tyrosine kinase inhibitors[J]. Acta Oncol, 2009,48(7):964-970.
[8] SCHMIDINGER M, ZIELINSKI C C, VOGL U M, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2008,26(32):5204-5212.
[9] AI D, BANCHS J, OWUSU-AGYEMANG P, et al. Chemotherapy induced cardiovascular toxicity:beyond anthracyclines[J]. Minerva Anestesiol, 2014,80(5):586-594.
[10] DOHERTY K R, WAPPEL R L, TALBERT D R, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes[J]. Toxicol Appl Pharm, 2013,272(1):245-255.
[11] TRUONG J, YAN A T, CRAMAROSSA G, et al. Chemotherapy-induced cardiotoxicity:detection, prevention and management[J]. Can J Cardiol, 2014,30(8):869-878.
[12] ALBINI A, PENNESI G, DONATELLI F, et al. Cardiotoxicity of anticancer drugs:the need for cardio-oncology and cardio-oncological prevention[J]. J Natl Cancer Inst, 2010,102(1):14-25.
[13] FERRERO D, POGLIANI E M, REGE-CAMBRIN G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity[J]. Haematologica, 2006,91(6 Suppl):ECR27.
[14] REA D, BERGERON A, FIESCHI C, et al. Dasatinib-induced lupus[J]. Lancet, 2008,372(9640):713-714.
[15] SCHAID D J, SPRAGGS C F, MCDONNELL S K, et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury[J]. J Clin Oncol, 2014,32(22):2296-2303.
[16] YANO Y, NAMBA Y, MORI M, et al. Treatment of non-small-cell lung cancer with erlotinib following gefitinib-induced hepatotoxicity:review of 8 clinical cases[J]. Lung Cancer Int, 2012,2012:354657.
[17] MANCUSO A, ZAVAGLIA C, BAI F, et al. Letter:sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients[J]. Aliment Pharm Therap, 2013,38(11-12):1414-1416.
[18] SHAH R R, MORGANROTH J, SHAH D R. Hepatotoxicity of tyrosine kinase inhibitors:clinical and regulatory perspectives[J]. Drug Safety, 2013,36(7):491-503.
[19] BISSELL D M, GORES G J, LASKIN D L, et al. Drug-induced liver injury:mechanisms and test systems[J]. Hepatology, 2001,33(4):1009-1013.
[20] DU K, WILLIAMS C D, MCGILL M R, et al. The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation[J]. Toxicol Appl Pharm, 2013,273(3):484-491.
[21] IKEDA T. Idiosyncratic drug hepatotoxicity:strategy for prevention and proposed mechanism[J]. Curr Med Chem, 2014,22(4):528-537.
[22] DAHELE M, SENAN S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer:evidence for changing paradigms[J]. Cancer Res Treat, 2011,43(2):75-82.
[23] CHOI M K, HONG J Y, CHANG W J, et al. A phase Ⅱ trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations:implications of sensitive EGFR mutation test[J]. Cancer Chemoth Pharm, 2015,75(6):1229-1236.
[24] HERBST R S,PRAGER D, HERMANN R,et al. TRIBUTE:a phase Ⅲtrial of erlotinib hydrochloride(OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2005,23(25):5892-5899.
[25] YAMAGUCHI T, SEKI T, MIYASAKA C, et al. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma:an autopsy case report[J]. Oncol Lett, 2015,9(4):1633-1636.
[26] HARTMANN J T, KOLLMANNSBERGER C, CASCORBI I, et al. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer[J]. Invest New Drug, 2013,31(3):661-668.
[27] CARRILLO GARCÍA C. Role of growth/differentiation factor(GDF) 15 in the regulation of embryonic neural precursors[D]. Heidelberg:Ruperto-carola University of Heidelberg, 2008.
[28] SINGH S, SHI T, DUFFIN R, et al. Endocytosis, oxidative stress and IL-8 expression in human lung epithelial cells upon treatment with fine and ultrafine TiO 2:role of the specific surface area and of surface methylation of the particles[J]. Toxicol Appl Pharm, 2007,222(2):141-151.
[29] ZUEHLKE R L. Erythematous eruption of the palms and soles associated with mitotane therapy[J]. Dermatologica, 1974,148(2):90-92.
[30] SIL A, DAS N K.Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma[J]. Indian J Pharmacol, 2014,46(3):334-336.
[31] EDESA W A, ABDELMALEK R R. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt[J]. Asian Pac J Cancer P, 2015,16(5):1971-1976.
[32] WANG G S. Conjecture about hand-foot syndrome in CLASSIC Trial[J]. Iran J Public Health, 2014,43(4):534-534.
[33] LIN E H, CURLEY S A, CRANE C C, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer:potential benefits and COX-2 as the common mediator in pain, toxicities and survival[J]. Am J Clin Oncol Canc, 2006,29(3):232-239.
[34] CARONIA D, MARTIN M, SASTRE J, et al. A polymorphism in the cytidinedeaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J]. Clin Cancer Res, 2011,17(7):2006-2013.
[35] YAMAMOTO D, YAMAMOTO C, IWASE S, et al. Efficacy of vitamin E treatment for hand-foot syndrome in patients receiving capecitabine[J]. Breast Care, 2010,5(6):415-416.
[36] BRAIK T, YIM B, EVANS A T, et al. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy[J]. J Community Support Oncol, 2014,12(2):65-70.
[1] 郑艳榕,张翔南,陈忠. Nix介导的线粒体自噬机制的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 92-96.
[2] 李文龙,瞿海斌. 近红外光谱应用于中药质量控制及生产过程监控的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 80-88.
[3] 高思倩,沈咏梅,耿福能,李艳华,高建青. 糖尿病溃疡动物模型的建立及相关治疗研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 97-105.
[4] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 15-21.
[5] 高思倩,沈咏梅,耿福能,李艳华,高建青. 颞叶癫痫与海马成体神经再生[J]. 浙江大学学报(医学版), 2017, 46(1): 97-105.
[6] 李统宇 等. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报(医学版), 2016, 45(6): 648-654.
[7] 封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报(医学版), 2016, 45(6): 655-660.
[8] 曹鹏 等. 双氢青蒿素抗肿瘤分子生物学机制研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 501-507.
[9] 李亭亭 等. 中性粒细胞在哮喘中作用的研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 544-549.
[10] 王雪 等. TANK结合激酶1在抗病毒免疫应答中的作用研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 550-557.
[11] 历雪莹 等. DNA甲基化及其靶向治疗在急性髓系白血病中的研究进展[J]. 浙江大学学报(医学版), 2016, 45(4): 387-394.
[12] 竺天虹 等. 上皮间充质转化介导子宫内膜异位症发生发展的研究进展[J]. 浙江大学学报(医学版), 2016, 45(4): 439-445.
[13] 何斌 等. 贝伐珠单克隆抗体在难治性子宫颈癌中的应用进展[J]. 浙江大学学报(医学版), 2016, 45(4): 395-402.
[14] 杜苗苗 等. 钙化性主动脉瓣疾病药物治疗研究进展[J]. 浙江大学学报(医学版), 2016, 45(4): 432-438.
[15] 徐玉兰 等. 秀丽隐杆线虫神经胶质细胞对神经系统发育和功能的影响[J]. 浙江大学学报(医学版), 2016, 45(3): 315-322.